People
Paradigm Shift Therapeutics (PSTx) was founded by biopharmaceutical industry veterans with the knowledge and passion to change drug development and commercialization
PSTx was launched in January 2014 by Teresa Burgess, PhD and Kate Farrell, PhD through an ongoing collaboration with Dr. David Roberts at the National Cancer Institute (NCI) focused on developing CD47-targeting inhibitors-a novel immune-checkpoint target with the potential to radically change treatment for cancer patients. Thomas Miller, PhD joined PSTx as a full partner in September 2014. Our public-private partnership with the National Institutes of Health (NIH) was expanded in September 2015 to launch a drug screening program with the National Center for Accelerating Translational Sciences (NCATS).
Leadership
Kate Farrell, PhD
CEO, Co-founder
-
23 years in early and late stage product development
-
16 years at Amgen (Research, Product Development, Operations, Commercialization)
-
5 years independent consulting
Teresa Burgess, PhD
CSO, Co-founder
-
20 years directing research and drug discovery at Amgen
-
2 discovery research projects to the clinic, one to Phase 3
-
Over a decade of leadership for CA Breast Cancer Research Program
Thomas Miller, PhD
COO, Co-founder
-
CD47 inventor; NCI Tech Transfer/Director’s Innovation awards
-
UCLA chemistry & pharmacology, NCI cancer research training
-
Target biology & assay development expert
Advisors and Collaborators
Jeffrey Rubin, MD PhD
Senior Investigator, Laboratory of Cell and Molecular Biology, National Cancer Institute (Retired)
Scientific Advisor
David Roberts, PhD
Chief, Biochemical Pathology Section at National Cancer Institute
Collaborator
James Inglese, PhD
Investigator at National Center for Advancing Translational Sciences (NCATS)
Collaborator
